Azepine Derivatives as 5-HT7 Receptor Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks effective 5-HT7 receptor modulators with good pharmacokinetic profiles for treating diseases related to body temperature regulation, biorhythms, sleep, and smooth muscles, as well as depression, migraine, anxiety, and pain.
Innovation Solution
Development of azepine derivatives and their pharmaceutically acceptable salts, which are synthesized through a Suzuki coupling reaction and used in pharmaceutical compositions to target 5-HT7 receptors, offering high binding affinities and antagonistic activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional 5-HT7 receptor antagonists (sulfonamide derivatives, tetrahydroisoquinoline derivatives) are used, then some receptor activity is achieved, but selectivity for 5-HT7 receptors and pharmacokinetic profiles are insufficient
Solution Approach 1:
The patent modifies molecular parameters by introducing specific substituents (R1 groups) at defined positions on the azepine core structure, changing electronic and steric properties to optimize both 5-HT7 receptor selectivity and pharmacokinetic behavior. This systematic parameter variation allows simultaneous improvement of selectivity and pharmacokinetic profiles.
Solution Approach 2:
The invention creates composite molecular structures by combining the azepine core with diverse aromatic substituents (phenyl, naphthyl, heteroaryl groups) and functional groups, resulting in molecules that exhibit both high 5-HT7 selectivity and improved pharmacokinetic properties that neither component alone would provide.
2Productivity
If existing 5-HT7 receptor modulators are developed, then some therapeutic effects are observed, but comprehensive efficacy across multiple disease conditions is limited
Solution Approach 1:
The patent introduces specific functional groups and substituents at precise locations on the azepine molecule to enhance interaction with the 5-HT7 receptor binding site while minimizing off-target effects. This localized modification approach improves therapeutic efficacy for multiple conditions without increasing side effects.
3Ease of manufacture
If simple azepine structures are used, then synthesis is easier, but binding affinity and antagonistic activity are insufficient
Solution Approach 1:
The patent divides the molecule into distinct functional segments: a core azepine structure for basic pharmacophore activity, and modular aromatic substituent groups (R1) that can be independently optimized for binding affinity. This segmentation allows systematic improvement of affinity while maintaining reasonable synthesis complexity through established coupling reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The azepine derivatives demonstrate high binding affinities and antagonistic activities on 5-HT7 receptors, effectively treating and preventing central nervous system diseases such as depression, migraine, anxiety, pain, and other related conditions.
Implementation Method 1
subjecting a compound of Formula 2 to the Suzuki coupling reaction with a compound of Formula 3
Data Source
AI summary
Azepine derivatives acting on 5-HT7 receptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HT7 receptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HT7 receptors antagonistic activity is required.